Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in ...

On August 21, 2025, Dynavax announced positive topline results from Part 1 of its Phase 1/2 clinical trial for Z-1018, a novel shingles vaccine candidate. The trial showed that Z-1018 has comparable ...

Dynavax (DVAX) stock gains as the company's Z-1018 shingles shot shows immune response comparable to GSK's (GSK) Shingrix vaccine in a Phase 1/2 trial. Read more here.

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

Dynavax Technologies Corp. (DVAX) on Thursday said that its experimental Shingles vaccine yielded positive results in an ...

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Dynavax delivers record Q2 results with $92M in HEPLISAV-B revenue, updates 2025 guidance, and advances pipeline milestones.

Key Points Dynavax Technologies (NASDAQ:DVAX) exceeded analyst expectations in Q2 2025, reporting GAAP revenue of $95.4 million and GAAP diluted EPS of $0.14. HEPLISAV-B, Dynavax's two-dose adult ...

Dynavax Technologies Corporation (NASDAQ: DVAX) Q2 2025 Earnings Call Transcript August 7, 2025 Dynavax Technologies ...

Dynavax believes the presentation of this non-GAAP financial measure, when viewed with its results under GAAP and the accompanying reconciliation, provide analysts, investors and other third ...